Korean Drug Co. Ltd (014570) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.046x

Based on the latest financial reports, Korean Drug Co. Ltd (014570) has a cash flow conversion efficiency ratio of 0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.72 Billion ≈ $2.52 Million USD) by net assets (₩81.04 Billion ≈ $54.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Korean Drug Co. Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Korean Drug Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Korean Drug Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Korean Drug Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Korean Drug Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Skye Bioscience, Inc. Common Stock NASDAQ:SKYE	-0.950x
Ginegar TA:GNGR	0.039x
Tai Twun Enterprise Co Ltd TW:3432	-0.099x
Aetherium Acquisition Corp NASDAQ:GMFI	N/A
Cadence Opportunities Fund Ltd AU:CDO	0.000x
DNXcorp PA:ALDNX	0.018x
Almaden Minerals Ltd TO:AMM	-0.200x
EMB Mission Bound AB (publ) ST:NAVIGO-STAM	0.033x

Annual Cash Flow Conversion Efficiency for Korean Drug Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Korean Drug Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Korean Drug Co. Ltd stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩78.11 Billion ≈ $52.93 Million	₩4.87 Billion ≈ $3.30 Million	0.062x	+340.45%
2023-12-31	₩77.09 Billion ≈ $52.24 Million	₩-2.00 Billion ≈ $-1.35 Million	-0.026x	-137.14%
2022-12-31	₩84.71 Billion ≈ $57.41 Million	₩5.91 Billion ≈ $4.01 Million	0.070x	-39.22%
2021-12-31	₩76.69 Billion ≈ $51.97 Million	₩8.81 Billion ≈ $5.97 Million	0.115x	-34.00%
2020-12-31	₩70.87 Billion ≈ $48.03 Million	₩12.33 Billion ≈ $8.36 Million	0.174x	+82.29%
2019-12-31	₩65.05 Billion ≈ $44.08 Million	₩6.21 Billion ≈ $4.21 Million	0.095x	+3.56%
2018-12-31	₩62.80 Billion ≈ $42.56 Million	₩5.79 Billion ≈ $3.92 Million	0.092x	+1074.16%
2017-12-31	₩56.97 Billion ≈ $38.61 Million	₩447.20 Million ≈ $303.06K	0.008x	-89.37%
2016-12-31	₩53.66 Billion ≈ $36.37 Million	₩3.96 Billion ≈ $2.69 Million	0.074x	-40.18%
2015-12-31	₩49.68 Billion ≈ $33.67 Million	₩6.13 Billion ≈ $4.16 Million	0.123x	+34.95%
2014-12-31	₩48.79 Billion ≈ $33.06 Million	₩4.46 Billion ≈ $3.02 Million	0.091x	--

About Korean Drug Co. Ltd

KQ:014570 Korea Drug Manufacturers - General

Market Cap

$24.86 Million

₩36.68 Billion KRW

Market Cap Rank

#24424 Global

#1715 in Korea

Share Price

₩3390.00

Change (1 day)

-2.31%

52-Week Range

₩3120.00 - ₩4910.00

All Time High

₩13030.58